Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07750574Phase 2Not Yet Recruiting

Phase 2 Study of Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT03402399Not ApplicableUnknown

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

Showing all 3 trials

Research Network

Activity Timeline